Funnel plots assessing possible publication bias for clinicopathological features (A: lymph node involvement; B: clinical stage; C: cell differentiation; D: depth of invasion; E: gender; F: age).

<p>Funnel plots assessing possible publication bias for clinicopathological features (A: lymph node involvement; B: clinical stage; C: cell differentiation; D: depth of invasion; E: gender; F: age).</p

Forest plot estimating prognosis of patients with OSCC.

<p>Forest plot estimating prognosis of patients with OSCC.</p

The information size to demonstrate the relevance of survivin protein expression with lymph node metastasis.

<p>The dashed curve represents the cumulative Z-curve. The solid line represents the trial sequential monitoring boundary.</p

Funnel plot and sensitivity analysis for prognosis of patients with OSCC (A: Funnel plot; B: sensitivity analysis).

<p>Funnel plot and sensitivity analysis for prognosis of patients with OSCC (A: Funnel plot; B: sensitivity analysis).</p

Clinicopathological and methodological features of eligible studies.

<p>Clinicopathological and methodological features of eligible studies.</p

Flow diagram of the literature search process.

<p>Flow diagram of the literature search process.</p

Sensitivity analysis for clinicopathological features (A: lymph node involvement; B: clinical stage; C: cell differentiation; D: depth of invasion; E: gender; F: age).

<p>Sensitivity analysis for clinicopathological features (A: lymph node involvement; B: clinical stage; C: cell differentiation; D: depth of invasion; E: gender; F: age).</p

Additional file 1 of Inactivation of the T6SS inner membrane protein DotU results in severe attenuation and decreased pathogenicity of Aeromonas veronii TH0426

Additional file 1: Figure S1. Confirmation of the success and genetic stability of mutant strain ∆dotU and complemented strain C-dotU. (a) PCR detection of the mutant strain ∆dotU, M: DL5000 Marker; 1: the mutant strain ∆dotU; 2: wild type TH0426. (b) PCR detection of the complemented strain C-dotU, M: DL2000 Marker; 1: C-dotU; 2: TH0426. (c) Genetic stability of the partial deletion strain ∆dotU, M: DL5000 Marker; 1–10: ∆dotU; 11–12: TH0426; 13: control group. (d) Genetic stability of the partial complemented strain C-dotU, M: DL2000 Marker; 1–10: C-dotU; 11–12: TH0426; 13: control group. Figure S2. Flagellum straining and light microscopy observation of the three strains (the wild-type, ∆dotU and C-dotU). Light microscopy images of parental strain (A), ∆dotU (B) and C-dotU (C). Magnifications, 1000 × (A, B and C)

Additional file 1 of Oral vaccination with recombinant Lactobacillus casei expressing Aha1 fused with CTB as an adjuvant against Aeromonas veronii in common carp (Cyprinus carpio)

Additional file 1: Table S1. Information on the weight and length of all the healthy Cyprinus carpio (n=70 per group)

Image_1_Lytic Bacteriophage PZL-Ah152 as Biocontrol Measures Against Lethal Aeromonas hydrophila Without Distorting Gut Microbiota.JPEG

Phage therapy is an alternative approach to overcome the problem of multidrug resistance in bacteria. In this study, a bacteriophage named PZL-Ah152, which infects Aeromonas hydrophila, was isolated from sewage, and its biological characteristics and genome were studied. The genome contained 54 putative coding sequences and lacked known putative virulence factors, so it could be applied to phage therapy. Therefore, we performed a study to (i) investigate the efficacy of PZL-Ah152 in reducing the abundance of pathogenic A. hydrophila strain 152 in experimentally infected crucian carps, (ii) evaluate the safety of 12 consecutive days of intraperitoneal phage injection in crucian carps, and (iii) determine how bacteriophages impact the normal gut microbiota. The in vivo and in vitro results indicated that the phage could effectively eliminate A. hydrophila. Administering PZL-Ah152 (2 × 109 PFU) could effectively protect the fish (2 × 108 CFU/carp). Furthermore, a 12-day consecutive injection of PZL-Ah152 did not cause significant adverse effects in the main organs of the treated animals. We also found that members of the genus Aeromonas could enter and colonize the gut. The phage PZL-Ah152 reduced the number of colonies of the genus Aeromonas. However, no significant changes were observed in α-diversity and β-diversity parameters, which suggested that the consumed phage had little effect on the gut microbiota. All the results illustrated that PZL-Ah152 could be a new therapeutic method for infections caused by A. hydrophila.</p